Literature DB >> 10899653

The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia.

R A Perego1, M Costantini, G Cornacchini, L Gargantini, C Bianchi, E Pungolino, E Rovida, E Morra.   

Abstract

The Philadelphia chromosome, t(9;22)(q34;q11) gives rise more frequently, in chronic myeloid leukaemia (CML), to two BCR/ABL chimeric transcripts differing only by the absence of 75 nucleotides and defined as b2a2 and b3a2 types, encoding two 210-kDa tyrosine kinase proteins differing only by the absence of 25 amino acids coded by the b3 exon. In the present study the two transcripts, detected by RT-PCR in 88 consecutive unselected CML patients, were correlated with haematological findings at diagnosis and with the megakaryocyte size and frequency by morphometric evaluation of 45 bone marrow biopsies. The secondary structure prediction and hydrophobicity of the b2a2 and b3a2 type BCR/ABL protein were also obtained. The prediction results for the b3 exon amino acids using GOR IV and NnPredict methods showed a short beta strand corresponding to the hydrophobic portion of the peptide. Significantly higher values were found in the platelet count of patients carrying b3a2 transcripts. The megakaryocyte size and frequency in bone marrow biopsies did not show significant differences between the two groups of patients. Stratifying the patients on the basis of white blood cell (WBC) count below or above 100x10(9)/l we still had, in both groups, a significant difference in the platelet count between the b2a2 and b3a2 patients. The possible relationships between the structure of b2a2 and b3a2 types of BCR/ABL fused protein and thrombopoiesis are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899653     DOI: 10.1016/s0959-8049(00)00128-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  16 in total

1.  Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Authors:  Benjamin Hanfstein; Michael Lauseker; Rüdiger Hehlmann; Susanne Saussele; Philipp Erben; Christian Dietz; Alice Fabarius; Ulrike Proetel; Susanne Schnittger; Claudia Haferlach; Stefan W Krause; Jörg Schubert; Hermann Einsele; Mathias Hänel; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Markus Pfirrmann; Joerg Hasford; Wolf-Karsten Hofmann; Andreas Hochhaus; Martin C Müller
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

2.  Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.

Authors:  Preetesh Jain; Hagop Kantarjian; Keyur P Patel; Graciela Nogueras Gonzalez; Rajyalakshmi Luthra; Rashmi Kanagal Shamanna; Koji Sasaki; Elias Jabbour; Carlos Guillermo Romo; Tapan M Kadia; Naveen Pemmaraju; Naval Daver; Gautam Borthakur; Zeev Estrov; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal:  Blood       Date:  2016-01-04       Impact factor: 22.113

3.  Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl protein.

Authors:  Daniel Alvira; Ruth Naughton; Lavinia Bhatt; Sara Tedesco; William D Landry; Thomas G Cotter
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

4.  Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Andrea Davies; Katy Knight; Sarah J Watmough; Lihui Wang; Richard E Clark
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

5.  Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.

Authors:  Ayda Bennour; Ines Ouahchi; Bechir Achour; Monia Zaier; Yosra Ben Youssef; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Med Oncol       Date:  2012-12-27       Impact factor: 3.064

6.  Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report.

Authors:  Alexander Shimabukuro-Vornhagen; Achim Rothe; Lucia Nogova; Matthias Kochanek; Christoph Scheid; Michael von Bergwelt-Baildon
Journal:  J Med Case Rep       Date:  2011-05-30

7.  Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - a possible influence of mdr1 gene expression.

Authors:  Gueorgui Balatzenko; Babu Rao Vundinti; Guenova Margarita
Journal:  Hematol Rep       Date:  2011-03-23

8.  Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia.

Authors:  Abdul Hai; Nadeem A Kizilbash; Syeda Huma H Zaidi; Jamal Alruwaili; Khuram Shahzad
Journal:  Bioinformation       Date:  2014-03-19

9.  Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate.

Authors:  Pratik Deb; Prantar Chakrabarti; Shila Chakrabarty; Rajarshi Aich; Uttam Nath; Siddhartha Sankar Ray; Utpal Chaudhuri
Journal:  Indian J Med Paediatr Oncol       Date:  2014-01

10.  Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan.

Authors:  Najia Tabassum; Mohammad Saboor; Rubina Ghani; Moinuddin Moinuddin
Journal:  Pak J Med Sci       Date:  2014-07       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.